{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:59:13Z","timestamp":1794373153003,"version":"4.9.0"},"reference-count":320,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.1093\/ecco-jcc\/jjx009","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T13:27:21Z","timestamp":1485782841000},"page":"769-784","source":"Crossref","is-referenced-by-count":1083,"title":["Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management"],"prefix":"10.1093","volume":"11","author":[{"given":"Marcus","family":"Harbord","sequence":"first","affiliation":[{"name":"Imperial College London, and Chelsea and Westminster Hospital a , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Eliakim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chaim Sheba Medical Center b , Tel Hashomer , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Bettenworth","sequence":"additional","affiliation":[{"name":"Department of Medicine B, University Hospital M\u00fcnster, c M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Karmiris","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Venizeleio General Hospital d , Heraklion, Crete , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University and Medical School of Ioannina e , Ioannina , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tel-Hashomer Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University f , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kucharzik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Hospital L\u00fcneburg g , L\u00fcneburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University of Szeged h , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge i , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[{"name":"IBD Unit, Hull & East Yorkshire NHS Trust j , Hull , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Tavares","family":"de Sousa","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Algarve Hospital Center; Biomedical Sciences & Medicine Department, University of Algarve k , Faro , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Hospital l , Frankfurt\/Main , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU Bic\u00eatre, Universit\u00e9 Paris Sud m , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the European Crohn\u2019s and Colitis Organisation [ECCO]","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,28]]},"reference":[{"key":"key\n\t\t\t\t20170628064935_CIT0001","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0002","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","year":"1955","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170628064935_CIT0003","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","year":"1996","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0005","first-page":"CD004115","article-title":"Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0953-0673.1996.00327.x","article-title":"Distribution of mesalazine enemas in active and quiescent ulcerative colitis","volume":"10","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0007","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ibd.22939","article-title":"High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0008","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/ibd.21258","article-title":"Clinical trial: a novel high-dose 1 g mesalamine suppository [Salofalk] once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis","volume":"16","author":"International Salofalk Suppository OD Study Group","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0009","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10620-010-1334-y","article-title":"A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis","volume":"56","year":"2011","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170628064935_CIT0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ajg.2011.410","article-title":"Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis","volume":"107","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t20170628064935_CIT0012","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ibd.21193","article-title":"Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study","volume":"16","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0013","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-2036.2011.04840.x","article-title":"Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis\u2014a pooled analysis","volume":"34","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0014","first-page":"1867","article-title":"A double-blind comparison of oral vs rectal mesalamine vs combination therapy in the treatment of distal ulcerative colitis","volume":"92","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00042737-199606000-00010","article-title":"Beclomethasone dipropionate [3 mg] vs 5-aminosalicylic acid [2 g] vs the combination of both [3 mg\/2 g] as retention enemas in active ulcerative proctitis","volume":"8","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.40.6.775","article-title":"Rectal corticosteroids vs alternative treatments in ulcerative colitis: a meta-analysis","volume":"40","year":"1997","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0017","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.mib.0000231495.92013.5e","article-title":"Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials","volume":"12","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0018","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2015.01.037","article-title":"Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.crohns.2009.08.003","article-title":"Mesalazine vanishing time from rectal mucosa following its topical administration","volume":"4","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0021","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1111\/j.1572-0241.2008.02152.x","article-title":"Mesalamine foam enema vs mesalamine liquid enema in active left-sided ulcerative colitis","volume":"103","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0022","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1365-2036.2007.03468.x","article-title":"Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs a high-volume mesalazine foam in active distal ulcerative colitis","volume":"26","author":"International Salofalk Foam Study Group","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2036.2007.03349.x","article-title":"Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs 5-aminosalicylic acid in mild to moderate distal ulcerative colitis","volume":"26","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0024","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"4","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0025","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared with conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0026","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/apt.12266","article-title":"Randomised clinical trial: once- vs twice-daily prolonged-release mesalazine for active ulcerative colitis","volume":"37","author":"MOTUS study investigators","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0027","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from Cochrane reviews","volume":"19","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0028","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","article-title":"Delayed-release oral mesalamine at 4.8 g\/day [800 mg tablet] for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","article-title":"Effect of once- or twice-daily MTX mesalamine [SPD476] for the induction of remission of mild to moderately active ulcerative colitis","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once-daily, high-concentration MMX mesalamine in active ulcerative colitis","volume":"132","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20580","article-title":"Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis","volume":"15","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0032","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ajg.2015.114","article-title":"Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study","volume":"110","author":"BETA study participating centers","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0033","first-page":"CD007698","article-title":"Oral budesonide for induction of remission in ulcerative colitis","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0034","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study","volume":"143","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study","volume":"63","year":"2014","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.13076","article-title":"Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies","volume":"41","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0037","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2010.11.006","article-title":"3g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial","volume":"5","author":"International BUC-57 Study Group","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0038","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/ecco-jcc\/jju027.011","article-title":"OP011 Budesonide MMX\u00ae 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-ASAs","volume":"9","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0039","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/apt.13803","article-title":"Systematic review: second-generation vs conventional corticosteroids for induction of remission in ulcerative colitis","volume":"44","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0040","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa [mesalazine] is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","year":"2005","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0041","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gut.2008.154302","article-title":"Once daily vs three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial","volume":"58","author":"International Salofalk OD Study Group","year":"2009","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0042","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.crohns.2013.09.015","article-title":"Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2 g mesalazine dosing","volume":"8","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0043","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.cgh.2014.06.011","article-title":"Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/gut.1.3.217","article-title":"An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis","volume":"1","year":"1960","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0045","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/bmj.2.5321.1708","article-title":"Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis","volume":"2","year":"1962","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170628064935_CIT0046","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/bmj.2.5302.441","article-title":"Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone","volume":"2","year":"1962","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170628064935_CIT0047","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1365-2036.2003.01609.x","article-title":"Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study","volume":"17","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0048","first-page":"Cd007698","article-title":"Oral budesonide for induction of remission in ulcerative colitis","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.MIB.0000437495.30052.be","article-title":"Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn\u2019s disease, and pouchitis: meta-analysis of randomized controlled trials","volume":"20","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0050","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/11632710-000000000-00000","article-title":"Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients","volume":"72","year":"2012","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170628064935_CIT0051","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.v16.i15.1908","article-title":"Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis","volume":"16","year":"2010","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0052","first-page":"CD005573","article-title":"Probiotics for induction of remission in ulcerative colitis","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0053","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0054","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0055","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0016-5085(16)30517-0","article-title":"600 multi donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0056","first-page":"CD009400","article-title":"Helminth therapy [worms] for induction of remission in inflammatory bowel disease","volume":"1","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0057","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/ajg.2014.104","article-title":"First multicenter study of modified release phosphatidylcholine \u2018LT-02\u2019 in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0058","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ajg.2012.340","article-title":"Andrographis paniculata extract [HMPL-004] for active ulcerative colitis","volume":"108","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0059","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","article-title":"Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis","volume":"10","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ecco-jcc\/jjv224","article-title":"Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study","volume":"10","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0061","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gut.2009.192765","article-title":"Management of acute severe ulcerative colitis","volume":"60","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0062","first-page":"1067","article-title":"Intensive intravenous regimen for severe attacks of ulcerative colitis","volume":"1","year":"1974","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0063","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/bmj.39345.714039.55","article-title":"Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn\u2019s disease: record linkage studies","volume":"335","year":"2007","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170628064935_CIT0064","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bjs.6874","article-title":"Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications","volume":"97","year":"2010","journal-title":"Br J Surg"},{"key":"key\n\t\t\t\t20170628064935_CIT0065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/codi.12328","article-title":"Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis","volume":"15","year":"2013","journal-title":"Colorectal Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0066","first-page":"2001","article-title":"A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease","volume":"19","author":"Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0067","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/ajg.2011.386","article-title":"Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements","volume":"107","author":"Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0068","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/apt.12473","article-title":"Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit","volume":"38","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0069","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004836-199002000-00011","article-title":"High-dose methylprednisolone in the treatment of active ulcerative colitis","volume":"12","year":"1990","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1572-0241.2006.01007.x","article-title":"Continuous infusion vs bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0071","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine vs intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0072","first-page":"1025","article-title":"Randomized, double-blind comparison of 4 mg\/kg vs 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","year":"2003","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0073","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ibd.21847","article-title":"Toxic megacolon","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0074","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1572-0241.2001.03949.x","article-title":"Outcome of cytomegalovirus infections in patients with inflammatory bowel disease","volume":"96","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1099\/jmm.0.45629-0","article-title":"Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome","volume":"53","year":"2004","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170628064935_CIT0076","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ibd.20498","article-title":"Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy","volume":"14","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0077","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MIB.0000000000000675","article-title":"Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis","volume":"22","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0078","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"European Crohn\u2019s and Colitis Organisation [ECCO]","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0079","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ibd.20500","article-title":"Clostridium difficile and inflammatory bowel disease","volume":"14","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0081","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1572-0241.2007.01780.x","article-title":"A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients","volume":"103","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0082","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2036.2011.04661.x","article-title":"Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease","volume":"33","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0083","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1155\/2014\/914303","article-title":"Clostridium difficile infection worsens the prognosis of ulcerative colitis","volume":"28","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0084","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/apt.12073","article-title":"Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis","volume":"36","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ibd.22964","article-title":"Clostridium difficile infection in the inflammatory bowel disease patient","volume":"19","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0086","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.crohns.2011.09.005","article-title":"Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis","volume":"6","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0087","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/AAC.02606-13","article-title":"Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170628064935_CIT0088","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.crohns.2014.01.020","article-title":"Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations","volume":"8","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0089","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2009.05.031","article-title":"Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"European Crohn\u2019s and Colitis Organisation [ECCO]","year":"2009","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0091","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/gut.2010.228585","article-title":"Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study","volume":"60","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0092","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0093","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0094","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"European Crohn\u2019s and Colitis Organisation","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0095","first-page":"227","article-title":"Enteral vs parenteral nutrition as adjunct therapy in acute ulcerative colitis","volume":"88","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0096","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/gut.27.5.481","article-title":"Controlled trial of bowel rest in the treatment of severe acute colitis","volume":"27","year":"1986","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0097","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/j.1572-0241.2003.07696.x","article-title":"A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management","volume":"98","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0098","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0099","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00228-009-0719-3","article-title":"Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?","volume":"65","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170628064935_CIT0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00365521.2014.966753","article-title":"Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease","volume":"50","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ibd.21806","article-title":"Narcotic use for inflammatory bowel disease and risk factors during hospitalization","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0102","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/gut.27.10.1210","article-title":"Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis","volume":"27","year":"1986","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0103","first-page":"43","article-title":"Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis","volume":"89","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0104","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/00365520120413","article-title":"A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis","volume":"36","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"European Crohn\u2019s and Colitis Organisation [ECCO]","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/gut.2010.216895","article-title":"Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers","volume":"60","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0107","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"International Inflammatory Bowel Disease Genetics Consortium","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/gut.16.8.579","article-title":"Assessment of severity in colitis: a preliminary study","volume":"16","year":"1975","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0109","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00042737-199810000-00003","article-title":"Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis","volume":"10","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.13614","article-title":"Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data","volume":"43","author":"UK IBD Audit Steering Group","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0111","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.dld.2003.12.017","article-title":"Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment","volume":"36","year":"2004","journal-title":"Dig Liver Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0112","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/gut.32.12.1535","article-title":"Small bowel gas in severe ulcerative colitis","volume":"32","year":"1991","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0113","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(96)90808-9","article-title":"Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0114","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2036.2000.00705.x","article-title":"Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis","volume":"14","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0115","first-page":"1550","article-title":"Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity","volume":"39","year":"1994","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170628064935_CIT0116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjv047","article-title":"Association between the ulcerative colitis endoscopic index of severity [UCEIS] and outcomes in acute severe ulcerative colitis","volume":"9","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0117","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0118","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0119","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis [CONSTRUCT]: a mixed methods, open-label, pragmatic randomised trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0122","first-page":"CD004277","article-title":"Cyclosporine A for induction of remission in severe ulcerative colitis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0123","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Ciclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MCG.0b013e3181e883dd","article-title":"Cyclosporine is safe and effective in patients with severe ulcerative colitis","volume":"45","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1746.2009.06119.x","article-title":"Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis","volume":"25","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0126","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.crohns.2010.01.001","article-title":"Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines","volume":"4","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0127","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus [FK506] therapy in refractory ulcerative colitis","volume":"55","year":"2006","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0128","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus [FK506] in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","article-title":"Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis","volume":"10","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1572-0241.2006.00524.x","article-title":"Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease a long-term follow-up","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0131","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0132","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0133","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2036.2007.03383.x","article-title":"A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis","volume":"26","author":"Scottish Society of Gastroenterology Infliximab Group","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0134","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1365-2036.2010.04435.x","article-title":"Clinical trial: colectomy after rescue therapy in ulcerative colitis\u20143-year follow-up of the Swedish-Danish controlled infliximab study","volume":"32","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/apt.12387","article-title":"Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients","volume":"38","author":"Swedish Organization for the Study of Inflammatory Bowel Disease [SOIBD]","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0136","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00004836-200607000-00004","article-title":"Infliximab for hospitalized patients with severe ulcerative colitis","volume":"40","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0137","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2007.03300.x","article-title":"Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006","volume":"25","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ibd.20054","article-title":"Predictors of early response to infliximab in patients with ulcerative colitis","volume":"13","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0139","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imj.12397","article-title":"Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy","volume":"44","year":"2014","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20170628064935_CIT0140","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3748\/wjg.v19.i7.1091","article-title":"Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0141","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2010.09.004","article-title":"Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals","volume":"5","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0142","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.crohns.2014.01.006","article-title":"Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy","volume":"8","author":"Italian Group for the study of Inflammatory Bowel Disease [IG-IBD]","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0143","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0144","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/apt.13631","article-title":"Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0146","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2007.03415.x","article-title":"Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up","volume":"26","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0147","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0148","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","article-title":"Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis","volume":"20","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0149","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00384-012-1602-8","article-title":"Infliximab vs cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis","volume":"28","year":"2013","journal-title":"Int J Colorectal Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0151","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/MEG.0000000000000187","article-title":"Length of hospital stay and associated hospital costs with infliximab vs cyclosporine in severe ulcerative colitis","volume":"26","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0152","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/MIB.0000000000000808","article-title":"The next wave of biological agents for the treatment of IBD: evidence from Cochrane reviews","volume":"22","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0153","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ibd.20863","article-title":"Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis","volume":"15","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0154","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/BF02234594","article-title":"Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications","volume":"44","year":"2001","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t20170628064935_CIT0155","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0156","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s11605-008-0630-8","article-title":"Perioperative treatment with infliximab in patients with Crohn\u2019s disease and ulcerative colitis is not associated with an increased rate of postoperative complications","volume":"12","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"key\n\t\t\t\t20170628064935_CIT0157","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2036.2009.04204.x","article-title":"Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis","volume":"31","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0158","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1097\/MIB.0000000000000603","article-title":"Anti-tumor necrosis factor-\u03b1 antibody therapy management before and after intestinal surgery for inflammatory bowel disease: a CCFA position paper","volume":"21","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0159","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1097\/MIB.0000000000000919","article-title":"Preoperative anti-tumor necrosis factor therapy in patients with ulcerative colitis is not associated with an increased risk of infectious and noninfectious complications after ileal pouch-anal anastomosis","volume":"22","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1463-1318.2012.03188.x","article-title":"Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy","volume":"15","year":"2013","journal-title":"Colorectal Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0161","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/MIB.0000000000000350","article-title":"Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks?","volume":"21","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0162","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/apt.12688","article-title":"Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study","volume":"39","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0163","first-page":"A155","article-title":"Pattern and outcome of severe ulcerative colitis: 15 year data","volume":"54","year":"2005","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0164","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1572-0241.2007.01653.x","article-title":"Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis","volume":"103","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2036.2000.00697.x","article-title":"Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis","volume":"14","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0166","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0016-5085(85)90201-X","article-title":"Intensive intravenous treatment of ulcerative colitis","volume":"89","year":"1985","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0167","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0016-5085(94)90394-8","article-title":"A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis","volume":"106","year":"1994","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0168","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2036.2008.03841.x","article-title":"Rectal tacrolimus in the treatment of resistant ulcerative proctitis","volume":"28","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0169","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ibd.20644","article-title":"Local application of tacrolimus in distal colitis: feasible and safe","volume":"15","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0170","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1365-2036.2010.04293.x","article-title":"Infliximab for refractory ulcerative proctitis","volume":"31","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0171","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.12118","article-title":"Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis\u2014experience in 130 patients","volume":"37","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0172","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.40.4.485","article-title":"Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial","volume":"40","year":"1997","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0173","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1007\/BF02071409","article-title":"Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group","volume":"41","year":"1996","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170628064935_CIT0174","doi-asserted-by":"crossref","first-page":"A1073","DOI":"10.1016\/S0016-5085(98)84366-7","article-title":"Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety","volume":"114","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0175","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJMoa013136","article-title":"Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0176","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1155\/2002\/307218","article-title":"Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine vs oral mesalamine","volume":"16","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0177","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2036.1989.tb00247.x","article-title":"Safety and efficacy of acetarsol suppositories in unresponsive proctitis","volume":"3","year":"1989","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0178","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/apt.12369","article-title":"Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis","volume":"38","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0179","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/ajg.2009.388","article-title":"Appendicectomy as a therapy for ulcerative proctitis","volume":"104","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12893-015-0017-1","article-title":"The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial [NTR2883] and the ACCURE-UK trial: a randomised external pilot trial [ISRCTN56523019]","volume":"15","year":"2015","journal-title":"BMC Surg"},{"key":"key\n\t\t\t\t20170628064935_CIT0181","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2036.2011.04705.x","article-title":"Appendicectomy as a potential therapy for refractory ulcerative proctitis","volume":"34","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0182","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1318.2011.02600.x","article-title":"The effect of appendectomy on the course of ulcerative colitis: a systematic review","volume":"14","year":"2012","journal-title":"Colorectal Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0183","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gut.45.4.542","article-title":"Restorative proctocolectomy for distal ulcerative colitis","volume":"45","year":"1999","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0184","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","year":"2006","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0185","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ibd.21083","article-title":"Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis","volume":"16","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0186","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0187","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission","volume":"19","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0188","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0189","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"PURSUIT-Maintenance Study Group","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0191","first-page":"13","article-title":"Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial","volume":"5","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0192","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0193","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"GEMINI 1 Study Group","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0194","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study","volume":"43","author":"Vedolizumab Germany Consortium","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis","volume":"150","author":"European Crohn\u2019s and Colitis Organisation; Groupe d\u2019\u00c9tude Th\u00e9rapeutique des Affections Inflammatoires Digestives","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0196","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.crohns.2014.06.010","article-title":"Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids","volume":"8","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0197","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/MIB.0b013e318281f2b7","article-title":"52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and\/or immunosuppressants","volume":"19","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0198","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/apt.13531","article-title":"Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0199","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S0016-5085(16)30622-9","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0200","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"TOUCHSTONE Study Group","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0201","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Study A3921063 Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0202","first-page":"CD005112","article-title":"Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","volume":"3","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0203","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0204","first-page":"10","article-title":"52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and\/or immunosuppressants","volume":"5","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0205","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2036.2010.04380.x","article-title":"Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort","volume":"32","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0206","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"SONIC Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0207","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0208","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/MIB.0000000000000208","article-title":"Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD","volume":"20","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0209","first-page":"7","article-title":"Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn\u2019s disease: a single-center experience","volume":"14","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2036.2008.03764.x","article-title":"Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis","volume":"28","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0211","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0212","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0213","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/17474124.2015.1091307","article-title":"The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?","volume":"9","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0214","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/17474124.2015.1091304","article-title":"Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13","volume":"9","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474124.2015.1091306","article-title":"The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13","volume":"9","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0216","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","article-title":"Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis\u2014experiences from a single center","volume":"15","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0217","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0218","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO position statement on the use of biosimilars for inflammatory bowel disease\u2500an update","volume":"11","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0219","first-page":"117","article-title":"Mucosal healing with infliximab: results from the active ulcerative colitis trials","volume":"8","year":"2012","journal-title":"Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review article: defining remission in ulcerative colitis","volume":"34","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0221","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0222","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0223","first-page":"CD008655","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0224","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0225","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0226","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","article-title":"Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis","volume":"22","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000199914","article-title":"Ulcerative colitis in remission: it is possible to predict the risk of relapse?","volume":"44","year":"1989","journal-title":"Digestion"},{"key":"key\n\t\t\t\t20170628064935_CIT0228","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/gut.31.2.179","article-title":"Why do patients with ulcerative colitis relapse?","volume":"31","year":"1990","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0229","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/gast.2001.20912","article-title":"Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis","volume":"120","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0230","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1572-0241.2003.07717.x","article-title":"Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study","volume":"98","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0231","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1572-0241.2006.00476.x","article-title":"Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0232","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","year":"1991","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0233","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/BF02233941","article-title":"Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets","volume":"11","year":"1966","journal-title":"Am J Dig Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0234","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2016.50","article-title":"Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","year":"2003","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0236","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0237","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort [IBSEN Study]","volume":"44","author":"IBSEN Study Group","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0238","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ecco-jcc\/jju016","article-title":"Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies","volume":"9","year":"2015","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0239","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0240","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0016-5085(88)90677-4","article-title":"Comparison of delayed-release 5-aminosalicylic acid [mesalazine] and sulfasalazine as maintenance treatment for patients with ulcerative colitis","volume":"94","year":"1988","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0241","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0242","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/j.gastro.2009.12.054","article-title":"Once-daily dosing of delayed-release oral mesalamine [400 mg tablet] is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0243","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02065413","article-title":"Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group","volume":"40","year":"1995","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170628064935_CIT0244","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.14.12.923","article-title":"A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine [Salazopyrin]","volume":"14","year":"1973","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(65)90972-4","article-title":"Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis","volume":"285","year":"1965","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0246","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","article-title":"Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis","volume":"57","year":"2008","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0247","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ajg.2012.103","article-title":"Once-daily MMX[\u00ae] mesalamine for endoscopic maintenance of remission of ulcerative colitis","volume":"107","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0248","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0016-5085(98)70627-4","article-title":"Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group","volume":"114","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0249","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF02047216","article-title":"Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis","volume":"37","year":"1994","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t20170628064935_CIT0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study","volume":"42","year":"1998","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0251","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group","volume":"93","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0252","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0253","first-page":"A736","article-title":"The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis","volume":"106","year":"1994","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0254","first-page":"1079","article-title":"5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial","volume":"85","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0255","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1572-0241.2000.02185.x","article-title":"Long-term use of mesalamine [Rowasa] suppositories in remission maintenance of ulcerative proctitis","volume":"95","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0256","first-page":"CD004118","article-title":"Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"11","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0257","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ibd.20158","article-title":"Effect of weekend 5-aminosalicylic acid [mesalazine] enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study","volume":"13","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0258","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2036.1997.tb00001.x","article-title":"Oral or rectal administration of drugs in IBD?","volume":"11","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0259","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.crohns.2011.10.006","article-title":"Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing","volume":"6","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0260","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2036.2005.02458.x","article-title":"Comparison of two different daily dosages [2.4 vs 1.2 g] of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study","volume":"21","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0261","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"10","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0262","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Toronto Ulcerative Colitis Consensus Group","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0263","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2006.03058.x","article-title":"Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis","volume":"24","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0264","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2036.2010.04537.x","article-title":"Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis","volume":"33","author":"International Salofalk OD Study Group","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0265","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0266","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1542-3565(03)70032-9","article-title":"A pilot feasibility study of once daily vs conventional dosing mesalamine for maintenance of ulcerative colitis","volume":"1","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0267","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","article-title":"Randomised controlled trial of azathioprine withdrawal in ulcerative colitis","volume":"305","year":"1992","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170628064935_CIT0268","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","article-title":"Azathioprine in ulcerative colitis: final report on controlled therapeutic trial","volume":"4","year":"1974","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170628064935_CIT0269","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s005350200034","article-title":"The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis","volume":"37","year":"2002","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0270","first-page":"79","article-title":"Azathioprine vs sulfasalazine in maintenance of remission in severe ulcerative colitis","volume":"22","year":"2003","journal-title":"Indian J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0271","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0272","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/ajg.2009.410","article-title":"Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal","volume":"104","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0273","first-page":"1711","article-title":"The long-term outcome of ulcerative colitis treated with 6-mercaptopurine","volume":"91","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0274","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1365-2036.2002.01227.x","article-title":"The efficacy of methotrexate for maintaining remission in inflammatory bowel disease","volume":"16","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0275","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004836-199707000-00007","article-title":"Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis","volume":"25","year":"1997","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0276","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF02156261","article-title":"The role of azathioprine in the management of ulcerative colitis","volume":"33","year":"1990","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t20170628064935_CIT0277","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000007823","article-title":"Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience","volume":"62","year":"2000","journal-title":"Digestion"},{"key":"key\n\t\t\t\t20170628064935_CIT0278","first-page":"717","article-title":"The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis","volume":"85","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0279","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","year":"2002","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0280","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/MIB.0000000000000400","article-title":"Prognosis of patients with ulcerative colitis in sustained remission after thiopurines withdrawal","volume":"21","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0281","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/BF02100145","article-title":"Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses","volume":"41","year":"1996","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20170628064935_CIT0282","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-7-13","article-title":"Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study","volume":"7","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0283","first-page":"2498","article-title":"Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis","volume":"91","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0284","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis","volume":"2","year":"2008","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2013.09.032","article-title":"Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0286","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/ajg.2014.242","article-title":"Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0287","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/ctg.2016.24","article-title":"Maintenance of Efficacy and Continuing Safety of Golimumab for Active ulcerative colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year","volume":"7","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0288","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0289","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1756283X16643242","article-title":"Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis","volume":"9","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0290","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/14712598.2015.1044434","article-title":"Therapeutic drug monitoring of anti-TNF-\u03b1 agents in inflammatory bowel diseases","volume":"15","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0291","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0292","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0293","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease [IBD]: a meta-analysis","volume":"108","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0294","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0295","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0296","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0297","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170628064935_CIT0298","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0299","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"GEMINI 1 Study Group","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170628064935_CIT0300","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","article-title":"Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis","volume":"11","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0301","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","article-title":"Non-pathogenic Escherichia coli vs mesalazine for the treatment of ulcerative colitis: a randomised trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170628064935_CIT0302","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","year":"2004","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170628064935_CIT0303","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1055\/s-2008-1027463","article-title":"Probiotic Escherichia coli Nissle 1917 [EcN] for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study","volume":"46","year":"2008","journal-title":"Z Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0304","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/07315724.2003.10719276","article-title":"Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis","volume":"22","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"key\n\t\t\t\t20170628064935_CIT0305","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1365-2036.2006.02927.x","article-title":"Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis","volume":"23","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0306","first-page":"CD007443","article-title":"Probiotics for maintenance of remission in ulcerative colitis","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0307","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0016-5085(98)70104-0","article-title":"Ciprofloxacin as a treatment for ulcerative colitis not yet","volume":"115","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0308","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00004836-198908000-00008","article-title":"A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis","volume":"11","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0309","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","year":"1996","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0310","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2036.2009.04073.x","article-title":"Efficacy of methotrexate in Crohn\u2019s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine \/mercaptopurine","volume":"30","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0311","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1572-0241.2001.03624.x","article-title":"Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study","volume":"96","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0312","first-page":"CD007560","article-title":"Methotrexate for maintenance of remission in ulcerative colitis","volume":"8","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170628064935_CIT0313","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365521.1973.12096672","article-title":"The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year","volume":"8","year":"1973","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0314","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.1999.00473.x","article-title":"Is maintenance therapy always necessary for patients with ulcerative colitis in remission?","volume":"13","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170628064935_CIT0315","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170628064935_CIT0316","first-page":"156","article-title":"Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review","volume":"11","year":"2009","journal-title":"Curr Drug Targets"},{"key":"key\n\t\t\t\t20170628064935_CIT0317","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170628064935_CIT0318","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cgh.2016.05.044","article-title":"Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study","volume":"14","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170628064935_CIT0319","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170628064935_CIT0320","article-title":"European Crohn\u2019s and Colitis Organisation topical review on transitional care in inflammatory bowel disease","year":"2017","journal-title":"J Crohns Colitis"}],"updated-by":[{"DOI":"10.1093\/ecco-jcc\/jjab227","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"record-id":"35164"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/11\/7\/769\/45500603\/ecco-jcc_11_7_769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/11\/7\/769\/45500603\/ecco-jcc_11_7_769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:25:01Z","timestamp":1719030301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/11\/7\/769\/2962457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,28]]},"references-count":320,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,1,28]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,1,28]]}}}